A recent Obstetrics & Gynaecology digest,
as sent to subscribers

Study Type: Randomised, placebo-controlled clinical trial (single-region, US; 206 women randomised, 142 children assessed).

Key Question: Does maternal phosphatidylcholine supplementation (9000 mg/day from 16 weeks' gestation) improve childhood behaviour and cognition up to 4 years?

Key Findings:

• Fewer children had multiple or pervasive Withdrawn problems (CBCL) with phosphatidylcholine; the second primary outcome, Attention Problems, did not differ significantly.
• Secondary outcome: WPPSI-IV Full Scale IQ was higher by 7.78 points (95% CI 1.88–13.7; p=0.010).
• Exploratory analyses: autism-spectrum-range CBCL scores with language deficits in 1/71 vs 10/71 (RR 10.0, 95% CI 1.31–76.1) for placebo vs supplement. No increase in adverse maternal or neonatal outcomes reported.

Clinical Relevance: Patients may ask about choline supplementation, but this does not support a change in UK practice, which currently has no recommendation for supplementation at this dose.

Limitations: One-third attrition, parent-reported behavioural outcomes and a mostly exploratory autism finding with very wide confidence intervals limit the strength of the conclusions; the authors' recommended dose was derived post hoc and not tested directly.

Study Type: Systematic review with random-effects logistic regression (61 studies: 13 RCTs, 48 observational; PROSPERO-registered)

Key Question: Does bladder neck versus midurethral placement of retropubic autologous fascial slings differ in cure, improvement, or adverse events in women with stress or mixed urinary incontinence?

Key Findings:

• No significant difference in objective cure (74.0% vs 81.1%, OR 1.10 [0.37–3.28]) or subjective cure (70.8% vs 58.6%, OR 0.46 [0.19–1.10]) at median 2.4 years; improvement rates were also similar.
• Midurethral placement was associated with less de novo urgency (8.3% vs 15.0%, OR 0.50 [0.26–0.96]); other adverse events were comparable.
• Wide confidence intervals indicate imprecise estimates.

Clinical Relevance: For UK surgeons offering autologous fascial slings (e.g. after mesh restrictions), this suggests placement site may be tailored, with midurethral placement possibly preferable to limit de novo urgency.

Limitations: Moderate-to-high risk of bias across included studies, with predominantly observational data, so findings need confirmation in an RCT.

Study Type: Multicentre, partially randomised patient preference trial (three Italian tertiary centres), with a randomised cohort and a parallel preference cohort.

Key Question: In infertile women with ultrasound-diagnosed ovarian or deep endometriosis, does upfront IVF or surgery followed by natural conception give a higher live birth rate within 12 months?

Key Findings:

• Randomised cohort (n=55): live birth 57% (16/28) with IVF vs 26% (7/27) with surgery; RR 2.20 (95% CI 1.08–4.50; p=0.019).
• Preference cohort (n=75): live birth 64% (32/50) vs 28% (7/25); RR 2.29 (95% CI 1.18–4.43). Combined RR 2.29 (95% CI 1.41–3.70).
• Per-protocol and survival analyses were consistent with these results.

Clinical Relevance: Supports offering upfront IVF, rather than surgery for fertility purposes, to women with ultrasound-diagnosed endometriosis, relevant to NHS fertility pathways and shared decision-making. Pain and symptom outcomes were not reported in this abstract.

Limitations: Recruitment stopped early at 130 of 206 planned women, so the randomised cohort is small and underpowered, and the preference cohort is susceptible to selection bias.

Study Type: Pharmacovigilance disproportionality analysis (EudraVigilance spontaneous reports, 2016–2025)

Key Question: Is there a reporting signal for meningioma with estro-progestin or progestin-only contraceptives?

Key Findings:

• Desogestrel-only pills showed a clear signal: 110 reports, ROR 11.11 (95% CI 8.79–14.06), IC025 2.64, EB05 5.79.
• Drospirenone-only pills showed a weaker exploratory signal: 8 reports, ROR 2.41 (95% CI 1.19–4.89), IC025 0.54, EB05 1.17.
• No signal for drospirenone-ethinylestradiol, dienogest-ethinylestradiol or levonorgestrel; the authors stress this does not demonstrate safety.

Clinical Relevance: Desogestrel-only pills are widely prescribed in the UK, so this supports vigilance in counselling and in assessing new neurological symptoms during long-term use, alongside existing MHRA progestin-meningioma guidance.

Limitations: Spontaneous reporting provides no exposure denominators, latency data or confounder control, so findings are hypothesis-generating and cannot establish causality or compare risk between products.

Study Type: Prospective observational study (Scottish screening cohort, 2011–2015).

Key Question: How do cytology and hrHPV testing compare in predicting CIN2+ in young HPV-vaccinated women entering cervical screening?

Key Findings:

• hrHPV positivity was 86% in borderline/mild cytology and 27% in cytology-negative samples (10,000 co-tested samples). Of 1,352 colposcopy attenders, 184 had CIN2+.
• hrHPV testing: PPV 14.3% (95% CI 12.5–16.4), NPV 98.9% (94.0–99.9). High-grade cytology: PPV 71.7% (59.2–81.5), NPV 89.2% (87.4–90.8).
• hrHPV persistence fell with longer inter-test intervals (1,007 women with repeat testing).

Clinical Relevance: Supports cytology triage of hrHPV-positive samples in vaccinated cohorts, informing UK primary HPV screening where hrHPV positivity has low specificity.

Limitations: Predictive values derive from a selective colposcopy referral framework (verification bias), so they are not population-level accuracy estimates; the cohort was also screened from age 20 and received early vaccination, limiting applicability to current cohorts.

Study Type: Secondary (post hoc subgroup) analysis of a multicentre RCT (APRIL, Netherlands)

Key Question: Does low-dose aspirin reduce recurrent spontaneous preterm birth (PTB) in women whose previous PTB placenta showed maternal vascular malperfusion (MVM)?

Key Findings:

• Placental histology was available for 160/387 (41.3%) participants; MVM was present in 44 (27.5%).
• With MVM, recurrent PTB occurred in 1/24 (4.2%) on aspirin vs 9/20 (45.0%) on placebo (RR 0.09; 95% CI 0.01–0.43).
• Without MVM, recurrent PTB was 17/58 (29.3%) on aspirin vs 10/58 (17.2%) on placebo (RR 1.70; 95% CI 0.87–3.56; not significant).

Clinical Relevance: Placental histology after spontaneous PTB may help identify a vascular-mediated subgroup likely to benefit from aspirin, but this is hypothesis-generating and not yet a basis for changing UK practice.

Limitations: Very small subgroup numbers (44 with MVM; 10 events), post hoc analysis and histology available for only 41% of participants, so the effect size is likely imprecise and prone to bias.

Study Type: Systematic review and meta-analysis of 15 RCTs (PROSPERO-registered, PRISMA 2020, random-effects model).

Key Question: Does mifepristone for induction of labour at term reduce caesarean delivery compared with standard induction methods or placebo?

Key Findings:

• Caesarean rate was lower with mifepristone (33.1% vs 41.9%; OR 0.67, 95% CI 0.54–0.82); the effect persisted in placebo-controlled/high-quality trials (OR 0.58, 95% CI 0.40–0.83).
• Mifepristone was associated with higher 24-hour Bishop scores, shorter induction-to-delivery intervals, and reduced prostaglandin and oxytocin requirements.
• No differences in PPH, NICU admission, or Apgar <7 at 5 minutes, but most trials did not report these outcomes.

Clinical Relevance: Mifepristone is not an established induction agent in UK practice (NICE NG207 recommends prostaglandins, mechanical methods, or oxytocin), but these data may prompt consideration of adequately powered UK trials.

Limitations: Safety conclusions are weak because key maternal and neonatal outcomes were sparsely reported, and the abstract gives no detail on dosing heterogeneity or comparator variation across trials.

Study Type: Combined prospective (Hong Kong) and retrospective (Osaka) cohort study establishing normative biometry (n=956 fetuses).

Key Question: What are the normal region-specific growth trajectories of the fetal corpus callosum at 18-32 weeks on 3D transvaginal neurosonography, and does volume contrast imaging (VCI) alter measurements?

Key Findings:

• CC length, total area, and regional thicknesses showed non-linear growth. Genu and body thickness rose sharply from 18-23 weeks; genu then increased gradually, whereas body thickness plateaued before renewed growth at 31-32 weeks.
• Area expansion was posterior-predominant, greatest in the splenium (median ~0.40 cm² at 32 weeks).
• VCI and non-VCI measurements were comparable. Reproducibility was good-to-excellent, except moderate interobserver reliability for genu and body thickness.

Clinical Relevance: Provides a regional baseline for CC development that may inform future assessment of callosal anomalies, although the authors state it is not yet suitable for isolated clinical decision-making.

Limitations: Findings are from East Asian single-centre cohorts with no postnatal neurodevelopmental follow-up, so prognostic value and generalisability to UK populations are unestablished.